Startup profile for Angle Health: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Angle Health funding, valuation and investors

AI-native healthcare benefits platform for small businesses — level-funded plans with broker quoting and care navigation.

Keep track of Angle Health

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series C

$200M (+ $400M tender) · September 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$134M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth · San Francisco, CA, USA

Investors in latest funding

Lead: Vitruvian Partners

Other: Town Hall Ventures , Blumberg Capital , Portage Ventures , PruVen Capital , Y Combinator

Sources: latest funding Last verified: 2026-09-19

Overview

Angle Health (not Angle Protocol / angle.money) is a San Francisco healthcare benefits company that sells level-funded health plans and AI-native plan administration to small and midsize employers. Founded by ex-Palantir engineers including CEO Ty Wang, it is a Y Combinator Winter 2020 alum. On September 18, 2026 the company announced a $600 million equity financing package at a $2.7 billion valuation: $200 million Series C led by Vitruvian Partners plus a $400 million tender offer for employee and early-investor liquidity. Town Hall Ventures joined; Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator returned. Closing is expected later in September. Company claims include 120% YoY growth, median renewal increases of 5–7% vs ~18% SMB market median (Morgan Health / company), plans in 47 states, and nearly $1 billion in annualized premium-equivalents. The Wall Street Journal reported the secondary priced near $2.5B — below the primary mark. Do not confuse with the DeFi stablecoin protocol at /startup/angle.

Why Angle Health is interesting

September 18, 2026: Vitruvian led a $200M Series C (plus $400M tender) at $2.7B for a YC W20 company that says it serves 5,000+ employers, ~$1B premium-equivalents, and four consecutive quarters of EBITDA and GAAP profitability — rare growth software economics in SMB health insurance.

Product & use cases

Benefit Builder and Quote-to-Card platforms let brokers generate underwritten quotes from a census, customize level-funded plans, and issue coverage. AI navigation and condition-specific care pathways sit on top of plan administration for employers with as few as two employees (state-dependent).

  • SMB employers seeking level-funded plans between fully insured and self-funded
  • Brokers needing fast underwritten quotes and plan customization
  • Employees needing AI-assisted navigation into lower-cost care pathways

Key facts

  • Sep 18, 2026: $200M Series C + $400M tender at $2.7B (company); close expected later in September
  • Vitruvian led; Town Hall new; Blumberg, Portage, PruVen, YC returning
  • Company: 5,000+ employers, ~$1B premium-equivalents, 4 quarters EBITDA + GAAP net income
  • WSJ: secondary near $2.5B — do not treat tender as primary at $2.7B

Funding history (newest first)

Series C

2026-09 $200M (+ $400M tender)
  • Vitruvian Partners (lead)
  • Town Hall Ventures (participant)
  • Blumberg Capital (participant)
  • Portage Ventures (participant)
  • PruVen Capital (participant)
  • Y Combinator (participant)

Source: Https://www.anglehealth.com/post/angle-health-secures-series-c-financing

Series B

2025-12 $134M (WSJ on prior)
  • Portage Ventures (lead)

Source: Https://thenextweb.com/news/angle-health-600m-vitruvian-partners-2-7bn-valuation

Competitive landscape

Edge: Company-disclosed profitability plus renewal pricing below market benchmarks is the diligence hook versus pure ICHRA or broker-tool startups that lack an insurance P&L.

Angle sells an insurance product plus admin software. Thatch sells ICHRA tooling. Do not treat a $2.7B mark as interchangeable with ICHRA platforms that disclose employer counts without premium-equivalents.

  • Thatch Health adjacent

    ICHRA / individual-budget benefits — different product from Angle’s level-funded group plans. See /startup/thatch-health.

  • Traditional carriers / TPAs incumbent

    Fully insured group plans and legacy admin stacks Angle positions against.

Market / IPO context

Editorial / static context — not a live quote.

Related funding articles

Venture Capital Tracker pieces that cover Angle Health's financing or category context.

FAQs about Angle Health

Practical answers founders, operators, and investors typically search for.

Angle Health announced a $600 million equity financing on September 18, 2026: $200 million Series C plus a $400 million tender offer, at a $2.7 billion valuation. Closing is expected later in September.
No. Angle Health is a U.S. healthcare benefits company. Angle Protocol (angle.money) is a DeFi stablecoin project covered separately at /startup/angle.
Vitruvian Partners led. Town Hall Ventures joined; Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator participated.
The company says it has delivered four consecutive quarters of EBITDA and GAAP net income profitability. Treat as company-disclosed, not audited figures published here.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.